Table 1 Patient characteristics by OAT and intracranial bleeding location

Male sex

18 (56.2%)

12 (48.0%)

p = 0.5994

16 (69.6%)

11 (78.6%)

p = 0.7099

Age

76.0 ± 13.4

78.5 ± 8.4

p = 0.5194

76.6 ± 10.4

82.1 ± 6.4

p = 0.1578

Age > 65 y

28 (87.5%)

23 (92.0%)

p = 0.6856

19 (82.6%)

14 (100%)

p = 0.2760

Height [m]

1.7 ± 0.1

1.7 ± 0.1

p = 0.3717

1.7 ± 0.1

1.7 ± 0.1

p = 0.8189

Weight [kg]

84.4 ± 16.0

76.9 ± 15.3

p = 0.0544

82.0 ± 25.6

83.4 ± 10.5

p = 0.3979

BMI [kg/m²]

28.1 ± 5.5

26.3 ± 5.1

p = 0.0619

26.7 ± 6.9

27.6 ± 5.2

p = 0.5700

Antiplatelet drugs

2 (6.2%)

2 (8.0%)

p = 1.0000

7 (30.4%)

4 (28.6%)

p = 1.0000

Indication

 Non-valvular arterial fibrillation

22 (68.8%)

20 (87.0%)

p = 0.3805

19 (82.6%)

11 (78.6%)

p = 1.000

 Deep vein thrombosis

3 (9.4%)

0 (0.0%)

p = 0.2481

1 (4.3%)

1 (7.1%)

p = 1.0000

 Other or unknown

7 (21.9%)

5 (20,0%)

p = 1.0000

3 (13.0%)

2 (14.3%)

p = 1.000

CHADS-VASC Score

4.7 ± 1.7

4.3 ± 1.6

p = 0.4736

4.9 ± 2.0

4.4 ± 1.1

p = 0.2893

HAS-BLED Score

2.8 ± 0.8

2.6 ± 1.1

p = 0.6929

2.5 ± 1.3

2.8 ± 1.0

p = 0.7086

HAS-BLED Score modified

2.7 ± 0.9

2.5 ± 1.0

p = 0.6616

2.4 ± 1.1

2.8 ± 1.0

p = 0.4513

Treatment

 Apixaban

10 (40%)

8 (57.1%)

 Edoxaban

1 (7.1%)

 Rivaroxaban

15 (60%)

5 (35.7%)

 Phenprocoumon

32

23